Chest
Volume 139, Issue 5, May 2011, Pages 1252-1253
Journal home page for Chest

Correspondence
FEV1/FVC Fixed Ratio Again!

https://doi.org/10.1378/chest.10-3148Get rights and content

Section snippets

To the Editor

I read with great interest in a recent issue of CHEST (November 2010) the Point/Counterpoint Editorials1, 2 on the FEV1/FVC fixed ratio of <0.7 to detect airflow obstruction and limitation. Although I was satisfied with the pro arguments of Drs Celli and Halbert,1 I found no real novel evidence on the con side compared with a similar debate I had on the same issue a few years ago.3, 4, 5 I still do not understand why Drs Enright and Brusasco2 criticized only the GOLD (Global Initiative for

References (18)

There are more references available in the full text version of this article.

Financial/nonfinancial disclosures: The author has reported to CHEST the following conflicts of interest: Dr Fabbri has served as a consultant to AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Medestea, Merck Sharp & Dohme, Nycomed, and Sigma Tau; he has been paid lecture fees by AstraZeneca, Boehringer-Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Nycomed, and Pfizer Inc; and he has received grant support from Almirall, AstraZeneca, Boehringer-Ingelheim, Menarini, Schering Plough, Chiesi Farmaceutici, Chiesi Foundation, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Nycomed, Pfizer Inc, Italian Ministry of Health, and Italian Ministry for University and Research.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).

View full text